A prospective evaluation in a randomized trial of the safety and efficacy of the use of the TAXUS Element paclitaxel-eluting coronary stent system for the treatment of de novo coronary artery lesions

Trial Profile

A prospective evaluation in a randomized trial of the safety and efficacy of the use of the TAXUS Element paclitaxel-eluting coronary stent system for the treatment of de novo coronary artery lesions

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Jun 2014

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Angina pectoris; Coronary artery disease; Coronary artery restenosis; Myocardial ischaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms PERSEUS-WH
  • Sponsors Boston Scientific Corporation
  • Most Recent Events

    • 31 Mar 2014 Final long-term 4 and 5 year results presented at the 63rd Annual Scientific Session of the American College of Cardiology.
    • 31 Mar 2014 Status changed from active, no longer recruiting to completed as reported at the 63rd Annual Scientific Session of the American College of Cardiology.
    • 11 Feb 2013 Planned end date changed from 1 Feb 2014 to 1 May 2014 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top